June’s first Dispatch reaches patients
Dispatch Bio’s virus therapy DV-10 enters phase 1.
Astra’s Datroway biomarker gives and it takes away
The QCS assay for TROP2 is being implemented more broadly, at the cost of further readout delays.
Erasca dips on patient death
ERAS-0015 data look good, but the company is punished for a pneumonitis death.
Pluvicto gets a no in Europe
Unlike the US FDA, the CHMP doesn't recommend approval for pre-chemo prostate cancer.
Crossover hits Compass
The Companion-002 trial of tovecimig fails to show an overall survival benefit versus chemo.
Relay passes the baton to atirmociclib
The move shows a gap developing between Relay and Lilly in PI3Kα inhibition.
